Zevra Therapeutics, Inc. reported second-quarter 2026 financial results, posting GAAP earnings per share of $0.14, which beat analyst estimates by $0.03. Revenue came in at $39.7 million, a 53.4% increase year-over-year, exceeding expectations by $5.82 million. The company held cash, cash equivalents, and investments totaling $260.2 million as of June 30, 2026, and believes its available financial resources are sufficient to execute on strategic priorities without relying on capital markets. As of the same date, total shares of common stock outstanding were 59,341,906, with fully diluted common shares at 69,298,105, including shares issuable from outstanding equity awards and warrants.
Zevra Therapeutics Inc.Beat EPS and revenue estimates with strong growth and sufficient cash.